Urolithin A
Selective mitochondrial recycling
Urolithin A activates mitophagy through pathways including PINK1/Parkin. Randomized human trials have studied mitochondrial biomarkers and muscle outcomes.
Evidence-led comparison

The short answer
Spermidine is the broader candidate for people interested in general autophagy biology and emerging cognitive or cardiovascular research, although larger human trials have produced mixed results. Urolithin A is the more targeted choice for mitochondrial quality and muscle-aging priorities, particularly through mitophagy activation, selected randomized human muscle outcomes, and consistent delivery independent of gut-microbiome conversion.
At a glance
The comparison is organized by biological role, evidence maturity, and the outcomes each ingredient is best positioned to support.
| Dimension | Urolithin A | Spermidine | Bottom line |
|---|---|---|---|
| Primary role | Activates mitophagy, selective recycling of damaged mitochondria | Influences broader autophagy and metabolic signaling | Targeted versus broad cellular recycling |
| Best-established human outcomes | Selected muscle endurance, strength, and mitochondrial biomarkers | Human outcome evidence is mixed; cognition is a major research focus | Urolithin A has clearer randomized muscle outcomes |
| Evidence base | Several randomized trials and a human systematic review | Strong preclinical rationale and a smaller intervention base | Mechanistic promise exceeds clinical certainty for spermidine |
| Typical studied intake | 500–1,000 mg daily | Human studies use varied extracts and doses | Products and doses are not interchangeable |
| Food relationship | Produced by some microbiomes from ellagitannins; conversion varies | Present in foods including wheat germ, soybeans, and mushrooms | Dietary exposure differs substantially |
| Most relevant goal | Mitochondrial quality, muscle endurance, healthy aging | Broad autophagy interest and exploratory cognition research | Goal and evidence tolerance determine fit |
Mechanisms
Urolithin A
Urolithin A activates mitophagy through pathways including PINK1/Parkin. Randomized human trials have studied mitochondrial biomarkers and muscle outcomes.
Spermidine
Spermidine is associated with wider autophagy-related signaling, including pathways involving AMPK and sirtuins, and has extensive preclinical research across aging biology.
Human evidence
Urolithin A evidence
Trials reported improvements in selected strength or endurance measures and favorable biomarkers. Several primary functional endpoints did not significantly improve, so broad anti-aging claims are not supported.
Spermidine evidence
A small pilot reported improved memory measures. The larger 12-month SmartAge trial did not significantly improve its primary memory outcome or secondary outcomes versus placebo; exploratory signals require validation.
Choosing by goal
Mitopure® is Amazentis’ proprietary, highly pure form of Urolithin A used in published human clinical studies. It provides a consistent dose for targeted mitophagy support. Spermidine has a broader autophagy hypothesis, but its human supplementation evidence remains less consistent for specific functional outcomes.
References
Common questions
